Avantor, Inc. (NYSE:AVTR) Shares Purchased by Hantz Financial Services Inc.

Hantz Financial Services Inc. boosted its holdings in shares of Avantor, Inc. (NYSE:AVTR) by 2.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 24,900 shares of the company’s stock after purchasing an additional 503 shares during the period. Hantz Financial Services Inc.’s holdings in Avantor were worth $644,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in AVTR. Versant Capital Management Inc lifted its holdings in shares of Avantor by 2,003.6% in the 2nd quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock valued at $25,000 after buying an additional 1,102 shares during the period. Blue Trust Inc. raised its position in Avantor by 1,830.3% during the second quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock valued at $31,000 after acquiring an additional 1,391 shares in the last quarter. UMB Bank n.a. acquired a new position in Avantor in the third quarter valued at approximately $49,000. Nisa Investment Advisors LLC boosted its position in Avantor by 69.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock worth $53,000 after purchasing an additional 835 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in shares of Avantor by 89.9% during the 3rd quarter. GAMMA Investing LLC now owns 2,715 shares of the company’s stock worth $70,000 after purchasing an additional 1,285 shares during the period. 95.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on AVTR shares. Wells Fargo & Company decreased their target price on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating for the company in a research note on Monday, October 28th. UBS Group decreased their price objective on shares of Avantor from $30.00 to $29.00 and set a “buy” rating for the company in a research report on Tuesday, October 8th. Barclays lowered their target price on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a research note on Friday, October 25th. Robert W. Baird reduced their price target on Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a report on Monday, October 28th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $34.00 price target on shares of Avantor in a research report on Thursday, September 26th. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.57.

Avantor Price Performance

Avantor stock opened at $21.06 on Monday. The company has a fifty day simple moving average of $23.28 and a 200-day simple moving average of $23.71. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84. The firm has a market capitalization of $14.33 billion, a price-to-earnings ratio of 45.78, a PEG ratio of 2.55 and a beta of 1.35. Avantor, Inc. has a 52-week low of $19.59 and a 52-week high of $28.00.

Insider Activity at Avantor

In other Avantor news, CAO Steven W. Eck sold 3,525 shares of the firm’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $25.06, for a total value of $88,336.50. Following the transaction, the chief accounting officer now directly owns 29,544 shares of the company’s stock, valued at $740,372.64. This trade represents a 10.66 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.50% of the stock is owned by corporate insiders.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.